Z0011001 (ZN-c3-016)
14 Sep 2023
Trial Summary
The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
Acronym:
Z0011001 (ZN-c3-016)
ACTRN/NCT /ethics:
NCT05743036
Scientific title:
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
Sponsor / Cooperative group:
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Trial & Patient Characteristics
| Cancer Type | Metastatic Colorectal Cancer |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I & Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2023-02-27 |
| Anticipated End Date | 2026-09-25 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| Pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Tim Price |
| Recruitment Status | Recruiting |